Antihypertensive treatment of acute cerebral hemorrhage (ATACH) II: Design, methods, and rationale

Neurocritical Care

Volumn 15, Issue 3, 2011, Pages 559-576

  Qureshi, A I ^a   Palesch, Y Y ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute hypertensive response; Clinical trial; Hematoma enlargement; Intracerebral hemorrhage; Randomization

Indexed keywords

ANTIHYPERTENSIVE AGENT; FUROSEMIDE; LABETALOL; NICARDIPINE; URAPIDIL;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; EFFECT SIZE; GLASGOW COMA SCALE; HOSPITAL DISCHARGE; HUMAN; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RATING SCALE; SAMPLE SIZE; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLASGOW COMA SCALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NICARDIPINE; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84856256507     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9538-3     Document Type: Article

References (84)

1. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450-60. (Pubitemid 32402103)
2. Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med. 2007;25:32-8. (Pubitemid 44869006)
3. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30:905-15. (Pubitemid 29156390)
4. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/ American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38: 2001-23. (Pubitemid 46850654)
5. Flaherty ML, Woo D, Haverbusch M, et al. Potential applicability of recombinant factor VIIa for intracerebral hemorrhage. Stroke. 2005;36:2660-4.
6. Steiner T, Kaste M, Forsting M, et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22:294-316. (Pubitemid 44338094)
7. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery. 2005;57:837-44.
8. Nishiyama T, Yokoyama T, Matsukawa T, Hanaoka K. Continuous nicardipine infusion to control blood pressure after evacuation of acute cerebral hemorrhage. Can J Anaesth. 2000;47:1196-201. (Pubitemid 32098995)
9. Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35:1364-7. (Pubitemid 38697459)
10. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5. (Pubitemid 27039454)
11. Mayer SA. Factor seven for acute hemorrhagic stroke (FAST) study. In: 16th European Stroke Conference: Large Clinical Trials 1. Abstract 1 29 May-1 June 2007.
12. Mayer SA, Davis SM, Begtrup K, et al. Subgroup analysis in the Fast trial: A subset of intracerebral hemorrhage patients that benefit from recombinant activated factor VII. Stroke. 2008;39: 528.
13. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27:1783-7. (Pubitemid 26332505)
14. Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology. 1994;44:1379-84. (Pubitemid 24247421)
15. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality [see comment]. Stroke. 1993;24: 987-93. (Pubitemid 23201455)
16. Qureshi AI, Safdar K, Weil J, et al. Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke. 1995;26:1764-7.
17. Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage [see comment]. Stroke. 2001;32:891-7.
18. Godoy DA, Pinero G, Di Napoli M. Predicting mortality in spontaneous intracerebral hemorrhage: can modification to original score improve the prediction? Stroke. 2006;37:1038-44.
19. Nilsson OG, Lindgren A, Brandt L, Saveland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg. 2002;97: 531-6. (Pubitemid 34994368)
20. Qureshi AI, Geocadin RG, Suarez JI, Ulatowski JA. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. Crit Care Med. 2000;28:1556-64. (Pubitemid 30324539)
21. European Stroke Initiative Writing C, Writing Committee for the EEC, Katse M, et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22:294-316.
22. St Louis EK, Wijdicks EF, Li H. Predicting neurologic deterioration in patients with cerebellar hematomas. Neurology. 1998; 51:1364-9. (Pubitemid 28520559)
23. Sumer MM, Acikgoz B, Akpinar G. External ventricular drainage for acute obstructive hydrocephalus developing following spontaneous intracerebral haemorrhages. Neurol Sci. 2002;23:29-33. (Pubitemid 34591415)
24. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage [see comment]. Crit Care Med. 1999;27:617-21. (Pubitemid 29162685)
25. Bhattathiri PS, Gregson B, Prasad KSM, Mendelow AD, Investigators S. Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial. Acta Neurochir Suppl. 2006;96:65-8.
26. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767-73. discussion 773-764. (Pubitemid 44579589)
27. Lisk DR, Pasteur W, Rhoades H, Putnam RD, Grotta JC. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology. 1994;44:133-9. (Pubitemid 24029444)
28. PROGRESS Collaborative Group. Randomised trial of a perindopril- based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
29. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-37.
30. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program 2004; http://www.nhlbi.nih.gov/guidelines/ hypertension/jnc7full.pdf. Accessed April 2011.
31. Qureshi AI, Hutson AD, Harbaugh RE, et al. Methods and design considerations for randomized clinical trials evaluating surgical or endovascular treatments for cerebrovascular diseases. Neurosurgery. 2004;54:248-64. discussion 264-7.
32. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000;321:504. (Pubitemid 30623610)
33. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what [see comment]. Lancet. 2002;359:696-700. (Pubitemid 34203775)
34. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-7.
35. Wilson JT, Hareendran A, Grant M, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002;33:2243-6. (Pubitemid 35014637)
36. Choi SC, Clifton GL, Marmarou A, Miller ER. Misclassification and treatment effect on primary outcome measures in clinical trials of severe neurotrauma. J Neurotrauma. 2002;19:17-22. (Pubitemid 34117093)
37. Mayer SA. Recombinant activated factor VII for acute intracerebral hemorrhage. Stroke. 2007;38:763-7. (Pubitemid 46184255)
38. Greup TE. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:99-208.
39. Segal ME, Schall RR. Determining functional/health status and its relation to disability in stroke survivors. Stroke. 1994;25:2391-7. (Pubitemid 24359307)
40. Dorman PJ, Waddell F, Slattery J, Dennis M, Sandercock P. Is the EuroQol a valid measure of health-related quality of life after stroke? Stroke. 1997;28:1876-82. (Pubitemid 27458988)
41. Dorman P, Slattery J, Farrell B, Dennis M, Sandercock P. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke. 1998;29:63-8. (Pubitemid 28046943)
42. Pickard AS, Johnson JA, Feeny DH, Shuaib A, Carriere KC, Nasser AM. Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and Health Utilities Index. Stroke. 2004;35:607-12. (Pubitemid 38174458)
43. Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke. 2007;38:2262-9. (Pubitemid 47457566)
44. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387-97. (Pubitemid 40179225)
45. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-37. (Pubitemid 351679599)
46. Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma. 2002;19:503-57. (Pubitemid 34587299)
47. Qureshi AI, Suri MFK, Nasar A, et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke. 2007;38: 2180-4. (Pubitemid 47012287)
48. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175-81. (Pubitemid 43739699)
49. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-85.
50. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391-9.
51. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63:484-9.
52. Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med. 2009;37:S69-74.
53. Adams HP Jr. Trials of trials in acute ischemic stroke. The Humana lecture. Stroke. 1993;24:1410-5.
54. Bolland K, Sooriyarachchi MR, Whitehead J. Sample size review in a head injury trial with ordered categorical responses. Stat Med. 1998;17:2835-47. (Pubitemid 28562979)
55. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5:603-12. (Pubitemid 43867434)
56. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-62. (Pubitemid 350035704)
57. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2009;72:1310-5.
58. Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics. 1990;46:1171-8.
59. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215-22. (Pubitemid 46237760)
60. Lai SM, Duncan PW. Stroke recovery profile and the Modified Rankin assessment. Neuroepidemiology. 2001;20:26-30. (Pubitemid 32171135)
61. Feinstein AR, Landis JR. The role of prognostic stratification in preventing the bias permitted by random allocation of treatment. J Chronic Dis. 1976;29:277-84.
62. Lipchik GL, Nicholson RA, Penzien DB. Allocation of patients to conditions in headache clinical trials: randomization, stratification, and treatment matching [see comment]. Headache. 2005;45: 419-28. (Pubitemid 40847164)
63. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials [see comment]. J Clin Epidemiol. 1999;52:19-26. (Pubitemid 29064270)
64. Beach ML, Meier P. Choosing covariates in the analysis of clinical trials. Control Clin Trials. 1989;10:161S-75S. (Pubitemid 20029383)
65. McHugh R, Matts J. Post-stratification in the randomized clinical trial. Biometrics. 1983;39:217-25.
66. Rectenwald JE, Upchurch GR Jr. Impact of outcomes research on the management of vascular surgery patients. J Vasc Surg. 2007;45(Suppl A):A131-40.
67. Lipscomb J, Donaldson MS, Hiatt RA. Cancer outcomes research and the arenas of application. J Natl Cancer Inst. 2004; Monographs:1-7.
68. Anonymous. Priorities for clinical research in intracerebral hemorrhage: report from a National Institute of Neurological Disorders and Stroke workshop. Stroke. 2005;36:e23-41.
69. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation. 2006;113:456-62. (Pubitemid 43803208)
70. Taylor SM, Robison JG, Langan EM 3rd, Crane MM. The pitfalls of establishing a statewide vascular registry: the South Carolina experience. Am Surg. 1999;65:513-8. discussion 518-519.
71. Isenberg SF. Community-based outcomes research: the project solo experience. Laryngoscope. 2000;110:21-3. (Pubitemid 30140372)
72. Qureshi AI, Suri MFK, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001. Neurosurgery. 2005;57:647-54. discussion 647-654.
73. Qureshi AI, Kirmani JF, Sayed MA, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology. 2005;64:2115-20. (Pubitemid 40881004)
74. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM, Cleveland Clinic Health System Stroke Quality Improvement T. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke. 2003;34: 799-800. (Pubitemid 36307415)
75. Anonymous. Comparison of patients with intracerebral hemorrhage treated within and outside clinical trials: A report of the antihypertensive treatment of acute cerebral hemorrhage investigators. In: American Academy of Neurology 59th Annual Meeting 2007. Boston. 2007.
76. Qureshi AI. Antihypertensive treatment of acute cerebral hemorrhage (ATACH): rationale and design. Neurocrit Care. 2007; 6:56-66. (Pubitemid 46424454)
77. Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217-20.
78. Haley EC Jr, Thompson JL, Levin B, et al. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke. 2005;36:1006-10. (Pubitemid 40629293)
79. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism [see comment]. Stroke. 1998;29:4-11. (Pubitemid 28046933)
80. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism [see comment]. JAMA. 1999;282:2003-11.
81. Investigators IMSS. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study [see comment]. Stroke. 2004;35:904-11.
82. Investigators IIT. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007;38:2127-35.
83. Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke. 2008;39:87-99.
84. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, Ezzeddine MA, Goldstein JN, Hussein HM, Suri MF, Tariq N, Antihypertensive Treatment of Acute Cerebral Hemorrhage Study Investigators. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010;67:570-6.